Loading the session
Loading the session
Loading instrument
$10.20
−2.44%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:43 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $10.45 on 4 Nov 2026: 59.2% below the 52-week high of $25.59 (25 Mar 2026) and 4.6% above the low of $9.99 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 decline of 26.9% was 11.0× its average daily move of 2.4% over the past year, and its largest one-day decline in a record that begins 26 Oct 2021.
Daily closes, split-adjusted · as of 4 Nov 2026
1 month: −39.8% (SPY −1.6%, XLV +13.5%). 3 months: −47.5% (SPY −0.4%, XLV +15.5%). 1 year: −31.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SNDX, SPY and XLV · as of 4 Nov 2026
4 Nov 2026 volume of 15.1M shares was 5.8× the average of the 30 sessions before it (2.6M), as the price fell 26.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
18.0M shares were sold short at the 15 Oct 2026 settlement, 20.3% of the 88.6M shares outstanding; covering them would take 7.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
November 4, 2026
−26.87%May 6, 2025
−21.59%November 12, 2024
−25.57%